BioVaxys enters into a major bioproduction agreement with Wuxi Biologics (Hong Kong) Ltd.

▴ BioVaxys enters into a major bioproduction agreement with Wuxi Biologics (Hong Kong) Ltd.

BioVaxys Technology Corp., the world leader in haptenized protein vaccines for antiviral and cancer applications, announced that it has entered into a major agreement of bioproduction with WuXi Biologics Limited ("WuXi"), world-leading contract development and research organization ("CDMO") and a business unit of Shanghai-based Wuxi AppTec, to produce SARS-CoV-2 s-required proteins by BioVaxys for BVX-0320, and its COVID-19 vaccine candidate, and for its Covid-T immunodiagnostic program.

Within the terms of the agreement on March 11, 2021, WuXi will synthesize comprehensive results of fully characterized SARS-CoV-2 Good Laboratory Practice (GLP) grade proteins for BioVaxys preclinical safety study of its COVID-diagnosis, this spring. Recombinant protein s will be constructed and expressed using WuXi Biologics' proprietary vector, with high protein production in a pilot plant bioreactor. By establishing its own protein source, rather than relying on a commercial bulk supplier, BioVaxys will be able to ensure the level of protein purity, consistency, and characterization required by the US Food and Drug Administration ("the FDA"), as well as the economics of generating your own protein supply,

The synthesized GMP-grade protein s is used in BioVaxys' Covid-T immunodiagnostics as well as BVX-0320, the company's SARS-CoV-2 vaccine candidate, which is also being prepared for this clinical study. anus. BioVaxys will submit its pre-IND petition to the FDA for Covid-T early next month.

Ken Kovan, CEO and COO of BioVaxys, stated: "Establishing a bioproduction method for a stable supply of purified and fully characterized protein s from a validated process will allow us to move quickly from having the GLP material to the next toxicity study. Covid-T ™ animal to have a stable source of GMP-grade proteins for clinical trials later this year. Now that we know the genetic sequences, an important benefit of our relationship with WuXi will be our ability to rapidly generate the proteins from emerging SARS-CoV-2 variants for use in a planned multivalent version of BVX-0320 and Covid-T  line extensions. "

James Passin, CEO of BioVaxys, commented: "We are delighted to execute a definitive agreement with WuXi Biologics, a China-based CDMO listed on the Hong Kong Stock Exchange under the symbol 2269, with a market capitalization of 45 billion US dollars. The relationship with WuXi positions BioVaxys to accelerate the regulatory and commercial advance of Covid-T and BVX-0320. "

For greater certainty, BioVaxys will make no express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.

Tags : #Biovaxys #WuxiBiologics #HongKong #CovidTreatment #CDMO #LatestpharmanNews

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

NRAI cautions restaurants about the dangers of aggregator payment gateways and deep discounting on diningDecember 09, 2024
Hot Cocoa: A Surprising Ally in Fighting Stress and Boosting Heart HealthDecember 09, 2024
What Your Headache Says About Your Health And Why It Can Be More Than Just a Temporary PainDecember 09, 2024
Hot Cocoa: A Surprising Ally in Fighting Stress and Boosting Heart HealthDecember 09, 2024
Is Your Favorite Snack a Secret Weapon Against Diabetes?December 07, 2024
Is the Fountain of Youth Hidden in Your Cells? Discover the Future of Ageing With Indian AIDecember 07, 2024
Does Your Heart Have a Mind of Its Own? Science Says Yes!December 07, 2024
Does Your Heart Have a Mind of Its Own? Science Says Yes!December 07, 2024
Heart Risks Are Shrinking Men’s Brains: What Science Reveals About Gender and AgingDecember 06, 2024
P&G India Celebrates 20 Years of P&G Shiksha with its largest ever Employee Volunteer Day Initiative across all offices and sitesDecember 06, 2024
Air India SATS Scales up Green Initiative with AeroWash Now Serving Two of India's Busiest AirportsDecember 06, 2024
The Silent Culprit Behind Osteoarthritis: Are Ultra-Processed Foods Eating Away our BonesDecember 06, 2024
From Daily Pills to 2 Shots Per Year: The Future of HIV ProtectionDecember 06, 2024
BREAKTHROUGH CLINICAL STUDY, FIRST OF ITS KIND, PROVES TRAYA CUSTOMIZED REGIMEN DELIVERS 3X* BETTER RESULTS THAN THE MOST PRESCRIBED HAIR GROWTH SERUM December 06, 2024
The Airborne Mutation: Is Bird Flu Becoming a Human Threat? December 05, 2024
Aster CMI Hospital collaborate with Government of Arunachal Pradesh Provide Affordable Liver Transplantation Services.December 05, 2024
Women missing out on treatment for their number one killerDecember 05, 2024
Packaged Water Under Fire: What FSSAI’s ‘High-Risk’ Tag Means for YouDecember 05, 2024
Life or Death: A New Breakthrough in Detecting Sepsis Before It’s Too LateDecember 05, 2024
Marble Centre International Unveils 'A Shared Memory' at Designuru 4.5December 05, 2024